Clinical Trials on Chronic Hepatitis C

Total 35745 results

Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
Hospices Civils de Lyon

Completed

Side Effects After Direct-acting Antiviral Treatment (EFINO-C)

Chronic Hepatitis c

France
Beni-Suef University

Completed

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Chronic Hepatitis C Virus Infection

Egypt
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients

Chronic Hepatitis C Infection

China
Sohag University

Recruiting

Long Term Follow up of Chronic HCV Patients Receiving DAAS

Chronic Hepatitis c

Egypt
Tongji Hospital

Unknown

Glecaprevir/Pibrentasvir Real-world Study in China

Chronic Hepatitis c
Hadassah Medical Organization
XTL Biopharmaceuticals

Withdrawn

Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers

Chronic Hepatitis C Virus Infection

Israel
Hadassah Medical Organization

Unknown

Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT

Chronic Hepatitis C Virus Infection

Israel
Beni-Suef University

Completed

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Chronic Hepatitis C Virus Infection
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients

Chronic Hepatitis C Infection

China
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

Chronic Hepatitis C Infection

China
Janssen R&D Ireland

Terminated

Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Chronic Hepatitis C Infection

Germany
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

Chronic Hepatitis c

China
Hospices Civils de Lyon

Completed

Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

Chronic Hepatitis c

France
Tripep AB
Inovio Pharmaceuticals

Unknown

Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Chronic Hepatitis C Virus Infection

Sweden
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects

Chronic Hepatitis c

China
AbbVie

Completed

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie (prior sponsor, Abbott)

Completed

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...

Recruiting

Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)

Chronic Hepatitis C Infection

China, Japan
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
Beker Laboratories
Pharmaceutical Research Unit, Jordan

Completed

Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)

Chronic Hepatitis c

Algeria
Radboud University Medical Center
Gilead Sciences

Unknown

Hepatitis C Elimination in the Netherlands (CELINE)

Chronic Hepatitis c

Netherlands
Postgraduate Institute of Medical Education and...
Directorate of Health and Family Welfare, Punjab

Unknown

DAA Therapy in Pediatric Patients With Chronic Hepatitis C

Chronic Hepatitis c

India
Postgraduate Institute of Medical Education and...
Directorate of Health and Family Welfare, Punjab

Unknown

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

Chronic Hepatitis c

India
Ain Shams University

Unknown

Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients

Chronic Hepatitis c

Egypt
Assiut University

Unknown

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

Chronic Hepatitis c

Egypt
Cairo University

Unknown

Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c

Chronic Hepatitis c

Egypt
MinaPharm Pharmaceuticals

Unknown

Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population (Quadritherapy)

Chronic Hepatitis c

Egypt
Cairo University
Egyptian Railway Hospital

Completed

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

Chronic Hepatitis c

Egypt
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

Chronic Hepatitis c

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Chronic Hepatitis c

China
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie

Completed

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)

Chronic Hepatitis C | Hepatitis C Virus | Genotype 3 Hepatitis C Virus
Valme University Hospital
Hospital General Universitario Elche; Hospital del SAS de Jerez; Clinica Universidad... and other collaborators

Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (FPSMON201401)

Chronic Hepatitis C Infection

Spain
AbbVie (prior sponsor, Abbott)

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Chronic Hepatitis C Infection

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)

Chronic Hepatitis C Infection
Virobay Inc.

Completed

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

Chronic Hepatitis C Infection

United States
University Health Network, Toronto

Completed

The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis

Chronic Hepatitis C Infection

Canada
Beijing Kawin Technology Share-Holding Co., Ltd.

Completed

Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Chronic Hepatitis c

China
Merck Sharp & Dohme LLC

Completed

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

Chronic Hepatitis C Infection
R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Chronic Hepatitis C Virus

United States, Puerto Rico
Mitsubishi Tanabe Pharma Corporation
Toray Industries, Inc

Completed

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Chronic Hepatitis C(CHC)

Japan
Merck Sharp & Dohme LLC

Completed

Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

Chronic Hepatitis C (HCV)
University Health Network, Toronto

Terminated

Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Chronic Hepatitis C - Genotype 3

Canada
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Chronic Hepatitis C Infection

3

Subscribe